Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera is expected to continue its upward trend in revenue growth, especially with the success of its Panorama and Horizon tests in the women's health sector, and the potential increase in revenue from its Signatera test for oncology minimal residual disease testing. The company has also shown impressive growth in its Signatera MRD business, with a record increase in test units and a projected expansion into 20+ solid tumor cancer states and 5 types of organ transplants. Additionally, with its ongoing development of a blood-based cancer detection test and its potential for companion diagnostic approvals, Natera is well-positioned to maintain its market leader status in the genetic testing industry.

Bears say

Natera is a diagnostic and research company with a diverse product portfolio, but the negative outlook is based on the potential for competition and regulatory challenges in the NIPT and liquid biopsy markets, reliance on lab partnerships, and the potential for pricing pressures due to Medicaid and Medicare coverage decisions. Additionally, the company's reliance on lab partnerships and potential ethical concerns surrounding genetic testing could also impact demand for its products. Overall, challenges in key markets and potential regulatory hurdles may limit the company's growth and profitability in the future.

Natera (NTRA) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 14 analysts, Natera (NTRA) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $259.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $259.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.